Aim: A recent large pooled survival analysis has shown that ipilimumab (ipi) conveys long-term survival benefit in a significant proportion of patients ( pts) with advanced melanoma (mel). We conducted a retrospective study of clinical outcomes and adverse events (AEs) among pts receiving ipi in a real world setting which may define whether longer survival is associated with increased HCRU. The present analysis describes HCRU by length of survival and baseline ECOG status. Methods: This medical chart review comprised adult pts in the US with unresectable stage III/IV mel treated in a community setting with ≥1 dose of ipi 3 mg/kg as first-line monotherapy between 04/2011 and 09/2012. Demographic/clinical characteristics, details of ipi dosing and subsequent therapies, AEs, and HCRU (hospitalizations, emergency department (ED) visits, nursing home stays) were collected. Pts were categorized according to survival (<1 year vs. ≥1 year) and baseline ECOG status (0 vs. ≥1). HCRU per pt was compared using ANOVA and chi-square tests. Results: Data were abstracted from 273 pt charts at 34 sites. As of 12/20/2013, 231 pts had been followed ≥1 year or until death, and 200 had ECOG status recorded. The 4 groups were similar in age (median 64 years), sex (66% male), and race (95% white). More hospitalizations per pt occurred among pts surviving <1 year vs. ≥1 year, and pts with ECOG status ≥1 vs. 0 ( p < 0.001 for both). Pts who survived <1 year had more hospitalizations and hospital days if their baseline ECOG status was ≥1 compared to 0, while ECOG status did not appear to impact HCRU among pts who survived ≥1 year. Conclusions: In this population, the rate of resource use was lower among those surviving ≥1 year than among those surviving <1 year. Baseline ECOG status ≥1 was associated with greater HCRU only among pts surviving <1 year. Prolonged survival appears to be associated with reduced HCRU among this patient population. 
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